查看中文
The Stock Exchange of Hong Kong Limited (HKEX) and Securities and Futures Commission (SFC) have announced a temporary relaxation of the minimum market capitalization requirements for Specialist Technology Company...more
8/30/2024
/ Capital Markets ,
Corporate Governance ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Listing Rules ,
Popular ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
With deep and liquid capital markets offering unique access to the Mainland China investor market, many international businesses are considering pursuing their IPOs in Hong Kong. This summary outlines key issues for companies...more
6/18/2024
/ Acquisitions ,
Asia Pacific ,
Capital Markets ,
China ,
Disclosure Requirements ,
Financial Services Industry ,
Global Market ,
Hong Kong ,
Initial Public Offering (IPO) ,
Intellectual Property Protection ,
Investment ,
Listing Rules ,
Mergers ,
Registration Requirement ,
Regulatory Agenda ,
Regulatory Requirements
查看中文
This update provides an overview of key regulatory developments in the fourth quarter of 2023 relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx) and their advisers....more
3/5/2024
/ Board of Directors ,
Capital Markets ,
Corporate Governance ,
Disclosure Requirements ,
Environmental Social & Governance (ESG) ,
Financial Regulatory Reform ,
Foreign Corporations ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Internal Controls ,
Listing Rules ,
Publicly-Traded Companies ,
Regulatory Agenda
查看中文
Following a market consultation process in late 2022, the Stock Exchange of Hong Kong Limited (HKEX) introduced a new regime to permit the listing of companies operating in specified specialist technology sectors....more
点击此处阅读调查报告全文
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing...more
4/25/2023
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
Corporate Governance ,
Foreign Corporations ,
Healthcare ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Life Sciences ,
Listing Rules ,
Popular ,
Publicly-Traded Companies
Like other global financial centers, Hong Kong has seen falling IPO volumes and volatile markets in 2022 in the face of challenging macroeconomic conditions and rising geopolitical tensions, including between China and the...more
12/14/2022
/ Capital Raising ,
China ,
Financial Markets ,
HKEx ,
Hong Kong ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Investors ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Repurchases ,
Stocks ,
Technology Sector ,
UK
With ongoing regulatory developments affecting capital markets globally, many China-related businesses are considering pursuing their IPOs in Hong Kong. However, the regulatory regime for IPOs on the Stock Exchange of Hong...more
Our second annual report on Hong Kong-listed biotech companies demonstrates the continued health of the sector. The report provides a comprehensive overview of the market in its current state, examining key data points for...more
Takeaways -
Greater China companies operating in any industry can now obtain secondary listings in Hong Kong, provided they meet market capitalization minimums.
Recent Listing Rules amendments also allow some companies...more
This update provides an overview of key regulatory developments in the past three months relevant to companies listed or planning to list on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In particular,...more
10/8/2021
/ Capital Markets ,
Corporate Governance ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Listing Rules ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
With ongoing regulatory developments affecting capital markets globally, many China-related businesses are considering pursuing their IPOs in Hong Kong. However, the regulatory regime for IPOs on the Stock Exchange of Hong...more
查看中文 - This update provides an overview of key regulatory developments in the past three months relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In...more
On February 23, 2018, the Stock Exchange of Hong Kong Limited (HKEX) published its consultation conclusions regarding a new chapter of its listing rules to facilitate the listings of pre-revenue biotech companies in Hong...more
Despite the impact of COVID-19 and other recent developments in Hong Kong, the city’s role as a center for China-based companies to raise capital became even more important in 2020. The momentum of several trends that began...more
1/29/2021
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
China ,
Foreign Relations ,
HKEx ,
Hong Kong ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
PCAOB ,
Publicly-Traded Companies ,
Securities and Exchange Commission (SEC)
The Hong Kong Stock Exchange continues to pursue and implement a number of rule changes aimed at making the listing process more efficient while strengthening and broadening its role overseeing listed companies and the tools...more
Despite political and economic uncertainties, markets and deal activity were resilient in 2019, and strong fundamentals remain in place heading into 2020. Companies continue to face a challenging litigation and enforcement...more
1/30/2020
/ Acquisitions ,
Administrative Procedure Act ,
Anti-Discrimination Policies ,
Anti-Harassment Policies ,
Anti-Kickback Statute ,
Antitrust Investigations ,
Appeals ,
Arbitration Awards ,
Attorney General ,
Backstop Agreements ,
BEPS ,
BitLicense ,
Blockchain ,
Board of Directors ,
Bonds ,
Capital Markets ,
CFIUS ,
CFTC ,
Chapter 11 ,
Claim Preclusion ,
Class Action ,
Commercial Bankruptcy ,
Common Stock ,
Congressional Investigations & Hearings ,
Congressional Subpoenas ,
Consumer Financial Protection Bureau (CFPB) ,
Cooperation Agreement ,
Copyright ,
Corporate Governance ,
Corporate Restructuring ,
Corporate Social Responsibility ,
Corporate Taxes ,
Corwin Doctrine ,
Covenant Lite Deals ,
Creditors ,
Cross-Border Transactions ,
DACA ,
DE Supreme Court ,
Debt Financing ,
Debtors ,
Department of Justice (DOJ) ,
Dischargeable Debts ,
Disgorgement ,
Disparate Impact ,
Dodd-Frank ,
Down Rounds ,
Drug Pricing ,
EBITDA ,
Employee Retirement Income Security Act (ERISA) ,
Employer Liability Issues ,
Employment Discrimination ,
Enforcement Actions ,
Enforcement of Foreign Judgments ,
Enterprise Act 2002 ,
Environmental Social & Governance (ESG) ,
EU ,
Fair Housing Act (FHA) ,
Federal Trade Commission (FTC) ,
FinTech ,
FIRRMA ,
Foreign Acquisitions ,
Foreign Investment ,
Foreign Issuers ,
FRCP 23 ,
General Data Protection Regulation (GDPR) ,
General Elections ,
GILTI tax ,
High-Yield Markets ,
Hong Kong ,
Hong Kong Stock Exchange ,
Individual Accountability ,
Initial Public Offering (IPO) ,
Intellectual Property Litigation ,
Intercreditor Agreements ,
International Arbitration ,
International Litigation ,
IRS ,
Issue Preclusion ,
Japan ,
Joint Venture ,
Legislative Agendas ,
Life Sciences ,
Listing Rules ,
Litigation Strategies ,
Make-Whole Premium ,
Mergers ,
MFW ,
Multinationals ,
National Security ,
PCAOB ,
Pharmaceutical Industry ,
Political Parties ,
Preferred Shares ,
Private Offerings ,
Privately Held Corporations ,
Proxy Advisory Firms ,
Publicly-Traded Companies ,
Refinancing ,
Regulatory Agenda ,
Reporting Requirements ,
SCOTUS ,
Securities and Exchange Commission (SEC) ,
Securities Litigation ,
Separation of Powers ,
Shareholder Activism ,
Shareholder Proposals ,
Shareholders ,
Split of Authority ,
State Labor Laws ,
Stock Drop Litigation ,
Tax Cuts and Jobs Act ,
Tax Litigation ,
Technology Sector ,
Third-Party Release Agrements ,
Transparency ,
UK ,
UK Brexit ,
Valuation ,
White Collar Crimes
This update provides an overview of key regulatory developments in the past three months relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In particular,...more
10/8/2019
/ Acquisitions ,
Censures ,
Consultation Periods ,
Corporate Issuers ,
Disclosure Requirements ,
Enforcement Actions ,
Fines ,
Foreign Issuers ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Listing Rules ,
Public Consultations ,
Security Token Offering (STOs) ,
Stock Connect ,
Takeovers
This edition provides an overview of key regulatory developments in the past three months relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In...more
7/5/2019
/ Accounting Standards ,
Acquisitions ,
Audit Policies ,
Board of Directors ,
CEOs ,
China ,
Conflicts of Interest ,
Controlling Stockholders ,
Criminal Prosecution ,
Disclosure Requirements ,
Disqualification ,
Due Diligence ,
Economic Sanctions ,
Enforcement Actions ,
Environmental Social & Governance (ESG) ,
Financial Reporting ,
Fines ,
Foreign Investment ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Insider Information ,
Listing Rules ,
Mergers ,
Non-GAAP Financial Measures ,
Office of Foreign Assets Control (OFAC) ,
Publicly-Traded Companies ,
Risk Assessment ,
The Market Misconduct Tribunal (MMT) ,
Trade Suspensions ,
Variable Interest Entities
This Hong Kong regulatory update provides an overview of key regulatory developments in the past three months relevant to companies listed (or planning to list) on The Stock Exchange of Hong Kong Limited (HKEx) and their...more
4/5/2019
/ Accounting Standards ,
Annual Reports ,
Best Practices ,
Censures ,
Corporate Governance ,
Disclosure Requirements ,
Due Diligence ,
Enforcement Actions ,
Environmental Social & Governance (ESG) ,
Failure to Comply ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Leases ,
Listing Rules ,
Material Misrepresentation ,
New Guidance ,
Omissions ,
Publicly-Traded Companies ,
Regulatory Standards ,
Securities ,
Shareholder Approval ,
Stock Connect ,
Weighted Voting Rights (WVR)
In April 2018, the Hong Kong Stock Exchange’s (HKEx) rule amendments permitting the listing of innovative, high-growth companies with dual-class share structures and pre-revenue biotech companies went into effect. The...more
1/23/2019
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
China ,
Dual Class Share Structures ,
Hong Kong ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Shanghai Stock Exchange ,
Shenzhen Stock Exchange (SZSE) ,
Stock Connect ,
Technology Sector ,
Trade Relations